A&C is pleased to announce today it has begun construction on a new manufacturing and storage facility in Baie D’Urfé, Quebec. The new site will increase the capacity of our high purity pharmaceutical excipients, buffers, process liquids and API’s to support our continued growth in Canada, USA and Europe.
The new facility will include a new state of the art buffer, process liquid and powder processing suites including warehousing that will meet and exceed cGMP Health Canada and FDA requirements for both Active Pharmaceutical Ingredients (API’s) and excipients used in pharmaceutical and biopharmaceutical manufacturing.
The facility will be completed and commissioned during the fourth quarter of this year and will add significantly to our capacity. We see this as a major commitment to our business to ensure a reliable supply to our valued partners in the pharmaceutical and biopharmaceutical industries. This investment will give A&C capacity and redundancy to serve our growing global customer base that is now serviced through key strategic locations in Canada, USA, and Europe.
Our customers can be assured that any products that will be affected will be addressed as per the cGMP requirements with the proper change control notification. It is A&C’s intention to qualify the new facility as a secondary manufacturing location prior to any change. This will ensure and further support A&C’s business continuity plan and help us service our customers for years to come.
A&C welcomes any audit requests which are now being scheduled for January 2017.
In line with our core values, this process will be conducted with complete transparency to ensure our customers are part of the process.
We look forward to providing further updates in the coming months.
